Cevimeline is a muscarinic receptor agonist (EC50s = 23, 48, and 63 nM for M1, M3, and M5, respectively, and >1 μM for M2 and M4).
CAS：107220-28-0
分子式：C10H17NOS.HCl
分子量：235.8
纯度：98%
存储：Store at -20°C

Background:

Cevimeline hydrochloride (AF102B hydrochloride) is a muscarinic M1 and M3 receptor agonist. Cevimeline hydrochloride acts a parasympathomimetic and muscarinic agonist used in the treatment of dry mouth associated with sjogren's syndrome.

参考文献:
[1]. Witsell DL, et al. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia.Head Neck. 2012 Aug;34(8):1136-42. doi: 10.1002/hed.21894. Epub 2012 Jan 9.
[2]. Ono K, et al. Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats.Arch Oral Biol. 2012 Apr;57(4):421-8. Epub 2011 Nov 17.
[3]. Kondo Y, et al.Cevimeline-induced monophasic salivation from the mouse submandibular gland: decreased Na+ content in saliva results from specific and early activation of Na+/H+ exchange.J Pharmacol Exp Ther. 2011 Apr;337(1):267-74. Epub 2011 Jan 14.
[4]. Voskoboynik B, et al.Cevimeline (Evoxac) overdose.J Med Toxicol. 2011 Mar;7(1):57-9.
[5]. Tajiri S, et al. Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations.Int J Pharm. 2010 Jan 4;383(1-2):99-105. Epub 2009 Sep 10.